BioMarin Pharmaceutical — Jan 12, 2026 release

3 Preliminary Financial Update Today 1 Item Guidance from Q3’25 Earnings Today’s Update FY 2025 Revenue $3,150M - $3,200M ~$3.2B VOXZOGO Revenue $900M - $935M ~$920M Q4 ROCTAVIAN Asset Write Down 2 Not Included ($0.60) – ($0.64) (Non-GAAP Diluted EPS Impact) Notes ▪ Q4 Roctavian asset write-downs are estimated to be $230M – $260M and include inventory, facilities, intangible assets, and severance costs, of which approximately $120M – $125M, or ($0.60) – ($0.64) per share, related to inventory is expected to reduce Non-GAAP Diluted EPS. ▪ Non-GAAP Diluted EPS guidance, excluding ROCTAVIAN asset write-down impact, remains unchanged, as the expected revenue result is partly offset by incremental Q4 operating expense. ▪ ROCTAVIAN revenue to be excluded from 2026 guidance. 1 2 Unaudited preliminary 2025 financial results; Non-GAAP Diluted EPS assumes approximately 200 million Weighted-Average Diluted Shares Outstanding 26